Genialis

We don't say, "we're like a family" Because we're not ?? We're a group of friends We imagine a world where precision medicine truly makes a difference And as we make it happen, we’re enjoying the ride together ??

If we had to sum up our #SITC24 insights in <100 words… 1?? AI and machine learning are driving deeper insights into the tumor immune microenvironment ?? Emerging concepts like immune "hubs" and "ecotypes" are reshaping our understanding of immune-tumor interactions ?? Spatial and RNA-based data are essential to these developments 2?? Next-generation immunotherapies are leading the conversation ?? CAR-T, bi- and tri-specific antibodies, and immune-stimulating antibody conjugates (ISACs) are gaining momentum 3?? Combination therapies are a key focus ?? New data pairs immune checkpoint inhibitors with agents like KRAS and DDR inhibitors ?? Precision modeling tools are essential to identify optimal combinations for specific tumor biologies For Genialis, these insights reaffirm our commitment to advancing precision oncology At SITC, we presented results on the Xerna? TME Panel, which demonstrated its predictive capability in identifying responders to HST-1011, a novel CBL-B inhibitor (https://lnkd.in/dTUjX_Hp) What excites you most about these developments?

Genialis has been named the winner of the Biomarker Discovery Platform of the Year award! ?? This honor comes from the BioTech Breakthrough Awards program, which conducts one of the industry’s most comprehensive evaluations of leading companies, solutions, and products: https://lnkd.in/gYXC6PQ5 Genialis was recognized for ????????????????? ??????????????, a first-in-class RNA- and ML-based biomarker.?Designed to predict treatment response and clinical benefit, krasID helps de-risk drug development and improve patient outcomes We’re proud to be recognized for our commitment to advancing RNA biomarkers that support every aspect of oncology clinical development – for every target, drug, and patient ??

"Personally, I don't find it that interesting to think about how I can build an AI system that ?????????????????? ?????????? ???????????? ?????? ?????????????? ???? I want to focus on how I can create AI systems that invent new types of things, that extrapolate beyond human knowledge I want to create things that solve problems humans ???????????? ?????? ??????????.” ?? In the latest episode of the Talking Precision Medicine podcast, we had the pleasure of hosting Charles Fisher, founder and CSO of Unlearn.AI Find the full episode here:????https://lnkd.in/dXevEDSB Joined by Genialis' CEO, Rafael Rosengarten, they explore: ??How digital twins of patients could lead to faster and more cost-effective clinical trials ??The balance between the size and quality of datasets that train predictive models ??Why Charles doesn't say he's an entrepreneur when he introduces himself at parties

?? One of the last chances to meet our team at 2024 events! IEEE BHI Conference ?? Another opportunity is at the AI Driven Drug Discovery Summit, where Genialis' Daniel Pointing will join an in-depth workshop on Ethical AI in Drug Discovery. See you in Boston on November 14th!

A major hurdle in oncology? ?? Predicting which patients will respond to treatment. This weekend at #SITC24, we're highlighting how biomarkers like Xerna? TME Panel can help. ?? Its potential as a predictive biomarker was demonstrated in the latest retrospective results from HotSpot Therapeutics, Inc.'s ongoing Phase 1 (SOLAR1) study. ? Analyses from a subset of patients suggested that those with ???????????????? ???? ???????????????? ?????????????? generally had ???????? ?????????? ???????????? ????????????. See the poster #1310 and meet our team tomorrow in Houston! This builds on our work with 7 cancer drugs of unique mechanisms. In every case, we’ve been able to define responder subgroups. ?? Learn more about our latest advancements and how our partnership with India-based 4baseCare is helping ensure our biomarkers benefit populations worldwide: https://lnkd.in/dTUjX_Hp

Digital technologies are transforming medical diagnostics ???????????? ???????? ????????. ?? But bringing AI into this field comes with its own set of challenges and opportunities. At yesterday's #BIOEurope2024, Genialis' CTO, Miha Stajdohar, joined a thought-provoking panel discussion, “Why Did It Have to Be Me?”: AI for Diagnosis, alongside Ralf Huss (BioM Biotech Cluster Development GmbH), David Krummen (Vektor Medical, Inc.), Andrea Gisle Joosen (Zühlke Group), and Andrea Riposati (Dante Labs). If you missed it, catch up with our team at #SITC24 this weekend or at #AIDDD next week!

?? Discover the Power of AI in Biopharma – Exclusive session – ?“Why Did It Have to Be Me?”: AI for Diagnosis AI is reshaping diagnostics! Discover how enhanced digital technologies are improving accuracy and efficiency in medical diagnostics in this session at #BIOEurope2024. ?? Date: Tuesday, November 5th ? Time: 16:45 - 17:30 ??Location: Room K1 ???? Moderator: Bora Erdemli, Partner at ZS Speakers include: Ralf Huss (BioM), David Krummen (Vektor Medical, Inc.), Andrea Gisle Joosen (Zühlke Group), Miha Stajdohar (Genialis) and Andrea Riposati (Dante Labs). #AIDiagnostics #BIOEurope2024 #AIforHealthcare #PrecisionMedicine #VentureCapital

The key to providing patients with the most suitable therapies? Biomarker testing. ?? That’s the focus of the poster we recently presented at #ENA24. In case you missed it, see it here: https://lnkd.in/d67WPS7S,? or connect with Genialis at upcoming events: ?? Miha Stajdohar joining a panel 'AI for Diagnosis' at #BIOEurope | November 5, 16:45 | Stockholm, Sweden ?? Poster presentation at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | November 9 | Houston, TX

From Friday runs to finish lines ?? After 6 months of training, our team conquered the 5k, 10k, and half marathon in Slovenske Konjice—with a 7kg chocolate boost at the end ??